TNFα and pathologic bone resorption
暂无分享,去创建一个
E. Schwarz | R. O’Keefe | L. Xing | Ping Li | Z. Yao | Qian Zhang | I. Badell | BrendanF. Boyce | Edward M. Schwarz | I. R. Badell | Brendan E Boyce
[1] E. Schwarz,et al. RANK Signaling Is Not Required for TNFα‐Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNFα‐Mediated Inflammatory Arthritis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] E. Schwarz,et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.
[3] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[4] W. Dougall,et al. A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.
[5] T. Takeya,et al. Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.
[6] J. Clohisy,et al. Tumor necrosis factor‐α mediates polymethylmethacrylate particle‐induced NF‐κB activation in osteoclast precursor cells , 2002 .
[7] A. Boskey,et al. In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] A R Pettit,et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.
[9] William Maloney,et al. Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.
[10] A. Mizokami,et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.
[11] F. Ross,et al. Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.
[12] Y. Kadono,et al. Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.
[13] Paul J. Williams,et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.
[14] E. Schwarz,et al. Efficacy of Etanercept for Wear Debris‐Induced Osteolysis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] S. Takeshita,et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.
[16] R. Pacifici,et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. , 2000, The Journal of clinical investigation.
[17] S. Goldring. The final pathogenetic steps in focal bone erosions in rheumatoid arthritis , 2000, Annals of the rheumatic diseases.
[18] K. Ikeda,et al. Prostaglandin E2 Induces Expression of Receptor Activator of Nuclear Factor–κB Ligand/Osteoprotegrin Ligand on Pre‐B Cells: Implications for Accelerated Osteoclastogenesis in Estrogen Deficiency , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] Y. Azuma,et al. Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts* , 2000, The Journal of Biological Chemistry.
[20] P. Kostenuik,et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. , 2000, Cancer research.
[21] T. Miyata,et al. Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.
[22] G. Karsenty. The genetic transformation of bone biology. , 1999, Genes & development.
[23] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[24] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[25] L. Hofbauer,et al. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. , 1999, European journal of endocrinology.
[26] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[27] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[28] J. Penninger,et al. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development , 1999, Immunology and cell biology.
[29] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[31] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[32] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[33] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[35] Ulrich Siebenlist,et al. Requirement for NF-κB in osteoclast and B-cell development , 1997 .
[36] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[37] J. Caamaño,et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2 , 1997, Nature Medicine.
[38] E. Jimi,et al. Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] E. Wagner,et al. Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.
[40] B. Spiegelman,et al. Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.
[41] S. Niida,et al. Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor , 1991, The Journal of experimental medicine.
[42] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[43] E. Schwarz,et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. , 2004, Arthritis and rheumatism.
[44] E. Schwarz,et al. Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice , 2004 .
[45] J. Clohisy,et al. Tumor necrosis factor-alpha mediates polymethylmethacrylate particle-induced NF-kappaB activation in osteoclast precursor cells. , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[46] T. Martin,et al. Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .
[47] A. Leonardi,et al. Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.